Table of Contents

company-logo

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Mesoblast Dividend Announcement

• Mesoblast does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Mesoblast dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Mesoblast Dividend History

Mesoblast Dividend Yield

Mesoblast current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Mesoblast stock? Use our calculator to estimate your expected dividend yield:

Mesoblast Financial Ratios

P/E ratio-169.49
PEG ratio-21.64
P/B ratio19.22
ROE-10.89%
Payout ratio0.00%
Current ratio1.18
Quick ratio1.18
Cash Ratio0.85

Mesoblast Dividend FAQ

Does Mesoblast stock pay dividends?
Mesoblast does not currently pay dividends to its shareholders.
Has Mesoblast ever paid a dividend?
No, Mesoblast has no a history of paying dividends to its shareholders. Mesoblast is not known for its dividend payments.
Why doesn't Mesoblast pay dividends?
There are several potential reasons why Mesoblast would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Mesoblast ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Mesoblast has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Mesoblast a dividend aristocrat?
Mesoblast is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Mesoblast a dividend king?
Mesoblast is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Mesoblast a dividend stock?
No, Mesoblast is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Mesoblast stocks?
To buy Mesoblast you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Mesoblast stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.